Literature DB >> 28824229

Pharmacogenetics and Personalized Medicine in Hematology.

Hara Prasad Pati1, Prashant Sharma2.   

Abstract

Year:  2017        PMID： 28824229      PMCID： PMC5544655          DOI： 10.1007/s12288-017-0847-3

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  12 in total

Review 1.  MAKING SENSE OF OUR VARIATION.

Authors:  Jeffrey Perkel
Journal:  Biotechniques       Date:  2015-11-01       Impact factor: 1.993

Review 2.  Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?

Authors:  Stella M Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

3.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

Review 4.  Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.

Authors:  D M Adcock; R Gosselin
Journal:  Thromb Res       Date:  2015-05-08       Impact factor: 3.944

Review 5.  New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.

Authors:  Rui Huang; Qian Kang; Huimin Liu; Yuhua Li
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

6.  Mutation Analysis in Chronic Myeloid Leukemia Patient in Chronic Phase on Imatinib Having Delayed Achievement of Milestones or Loss of Response.

Authors:  A K Tripathi; S P Verma; Nidhish Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2016-11-29       Impact factor: 0.900

7.  Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia.

Authors:  Korosh Ashrafi Dehkordi; Morteza Hashemzadeh Chaleshtori; Mohamadreza Sharifi; Ali Jalili; Fardin Fathi; Daem Roshani; Bahram Nikkhoo; Mohammad Saeed Hakhamaneshi; Mohammad Reza Mahmoodian Sani; Mahboue Ganji-Arjenaki
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-17       Impact factor: 0.900

Review 8.  Tim-3: an emerging target in the cancer immunotherapy landscape.

Authors:  Ana C Anderson
Journal:  Cancer Immunol Res       Date:  2014-05       Impact factor: 11.151

9.  TIM3 expression by leukemic and non-leukemic myeloblasts.

Authors:  Christine G Roth; Kelly Garner; Stephen Ten Eyck; Michael Boyiadzis; Lawrence P Kane; Fiona E Craig
Journal:  Cytometry B Clin Cytom       Date:  2013-03-29       Impact factor: 3.058

10.  The diploid genome sequence of an individual human.

Authors:  Samuel Levy; Granger Sutton; Pauline C Ng; Lars Feuk; Aaron L Halpern; Brian P Walenz; Nelson Axelrod; Jiaqi Huang; Ewen F Kirkness; Gennady Denisov; Yuan Lin; Jeffrey R MacDonald; Andy Wing Chun Pang; Mary Shago; Timothy B Stockwell; Alexia Tsiamouri; Vineet Bafna; Vikas Bansal; Saul A Kravitz; Dana A Busam; Karen Y Beeson; Tina C McIntosh; Karin A Remington; Josep F Abril; John Gill; Jon Borman; Yu-Hui Rogers; Marvin E Frazier; Stephen W Scherer; Robert L Strausberg; J Craig Venter
Journal:  PLoS Biol       Date:  2007-09-04       Impact factor: 8.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.